Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INSM Insmed	$158.29 -1.3%	$146.10	$60.40 ▼ $168.21	$33.47B	1.03	2.66 million shs	1.06 million shs
ONC BeOne Medicines	$310.98 -0.8%	$325.71	$170.99 ▼ $355.30	$34.08B	0.31	399,585 shs	79,372 shs
ROIV Roivant Sciences	$17.98 +0.1%	$14.35	$8.73 ▼ $18.42	$12.29B	1.2	6.28 million shs	2.21 million shs
TAK Takeda Pharmaceutical	$14.05 -0.6%	$14.78	$12.80 ▼ $15.69	$44.69B	0.21	2.60 million shs	495,471 shs

7 Stocks to Ride The A.I. Megaboom

We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INSM Insmed	-2.97%	-1.92%	+10.60%	+54.95%	+117.70%
ONC BeOne Medicines	-0.69%	-0.83%	-7.19%	+5.76%	+31,353,999,900.00%
ROIV Roivant Sciences	+0.50%	+5.71%	+20.21%	+57.82%	+53.11%
TAK Takeda Pharmaceutical	+0.14%	+1.95%	-6.05%	-3.62%	-0.04%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INSM Insmed	$158.29 -1.3%	$146.10	$60.40 ▼ $168.21	$33.47B	1.03	2.66 million shs	1.06 million shs
ONC BeOne Medicines	$310.98 -0.8%	$325.71	$170.99 ▼ $355.30	$34.08B	0.31	399,585 shs	79,372 shs
ROIV Roivant Sciences	$17.98 +0.1%	$14.35	$8.73 ▼ $18.42	$12.29B	1.2	6.28 million shs	2.21 million shs
TAK Takeda Pharmaceutical	$14.05 -0.6%	$14.78	$12.80 ▼ $15.69	$44.69B	0.21	2.60 million shs	495,471 shs

7 Stocks to Ride The A.I. Megaboom

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INSM Insmed	-2.97%	-1.92%	+10.60%	+54.95%	+117.70%
ONC BeOne Medicines	-0.69%	-0.83%	-7.19%	+5.76%	+31,353,999,900.00%
ROIV Roivant Sciences	+0.50%	+5.71%	+20.21%	+57.82%	+53.11%
TAK Takeda Pharmaceutical	+0.14%	+1.95%	-6.05%	-3.62%	-0.04%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INSM Insmed	2.86	Moderate Buy	$152.88	-3.42% Downside
ONC BeOne Medicines	2.90	Moderate Buy	$345.60	11.13% Upside
ROIV Roivant Sciences	2.80	Moderate Buy	$19.94	10.92% Upside
TAK Takeda Pharmaceutical	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest ROIV, TAK, INSM, and ONC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/20/2025	ONC BeOne Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$350.00 ➝ $383.00
10/20/2025	INSM Insmed	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$171.00
10/14/2025	INSM Insmed	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$140.00 ➝ $194.00
10/14/2025	TAK Takeda Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
10/8/2025	INSM Insmed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
10/8/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$345.00 ➝ $385.00
10/8/2025	ONC BeOne Medicines	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
10/8/2025	ROIV Roivant Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
10/3/2025	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$121.00 ➝ $196.00
10/2/2025	INSM Insmed	Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
10/2/2025	INSM Insmed	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$154.00 ➝ $193.00

(Data available from 10/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INSM Insmed	$363.71M	91.99	N/A	N/A	$1.60 per share	98.93
ONC BeOne Medicines	$4.56B	7.47	N/A	N/A	$34.10 per share	9.12
ROIV Roivant Sciences	$29.05M	422.54	N/A	N/A	$7.45 per share	2.41
TAK Takeda Pharmaceutical	$30.09B	1.49	$3.16 per share	4.44	$14.39 per share	0.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INSM Insmed	-$913.77M	-$5.71	N/A	N/A	N/A	-259.82%	-195.37%	-49.49%	10/30/2025 (Estimated)
ONC BeOne Medicines	-$644.79M	-$1.73	N/A	438.00	N/A	-3.89%	-1.22%	-0.72%	11/6/2025 (Confirmed)
ROIV Roivant Sciences	-$171.98M	-$0.70	N/A	N/A	N/A	-2,111.79%	-15.90%	-14.95%	11/11/2025 (Estimated)
TAK Takeda Pharmaceutical	$712.33M	$0.30	46.82	8.52	N/A	3.20%	10.50%	5.10%	10/30/2025 (Estimated)

Latest ROIV, TAK, INSM, and ONC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2025	Q2 2026	ROIV Roivant Sciences	-$0.27	N/A	N/A	N/A	$6.92 million	N/A
10/30/2025	Q3 2025	INSM Insmed	-$1.35	N/A	N/A	N/A	$114.33 million	N/A
10/30/2025	Q2 2026	TAK Takeda Pharmaceutical	$0.46	N/A	N/A	N/A	$8.01 billion	N/A
8/7/2025	Q2 2025	INSM Insmed	-$1.30	-$1.70	-$0.40	-$1.70	$104.06 million	$107.42 million
8/6/2025	Q2 2025	ONC BeOne Medicines	$0.48	$0.84	+$0.36	$0.84	$1.24 billion	$1.32 billion
7/30/2025	Q1 2026	TAK Takeda Pharmaceutical	$0.47	$0.52	+$0.05	$0.27	$7.96 billion	$7.45 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
INSM Insmed	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.55	3.91%	N/A	183.33%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INSM Insmed	0.45	6.68	6.33
ONC BeOne Medicines	0.04	1.95	1.72
ROIV Roivant Sciences	N/A	40.54	40.54
TAK Takeda Pharmaceutical	0.60	1.16	0.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INSM Insmed	N/A
ONC BeOne Medicines	48.55%
ROIV Roivant Sciences	64.76%
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
INSM Insmed	3.00%
ONC BeOne Medicines	6.62%
ROIV Roivant Sciences	10.80%
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INSM Insmed	1,271	211.38 million	205.03 million	Optionable
ONC BeOne Medicines	11,000	109.60 million	102.34 million	N/A
ROIV Roivant Sciences	860	682.88 million	609.13 million	Optionable
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable

ROIV, TAK, INSM, and ONC Headlines

Recent News About These Companies

Forum Financial Management LP Cuts Stake in Takeda Pharmaceutical Co. $TAK

5 hours ago | marketbeat.com

Takeda Pharmaceutical (TAK) Projected to Post Earnings on Thursday

October 23 at 5:51 AM | marketbeat.com

Takeda Pharmaceutical Company Limited (TAK) Discusses Global Strategic Collaboration for Next-Generation Oncology Assets and ADC Molecules Transcript

October 22 at 2:14 PM | seekingalpha.com

Takeda Pharmaceutical Company Limited (TAK) Discusses Global Strategic Collaboration for Next-Generation Oncology Assets and ADC Molecules - Slideshow

October 22 at 11:14 AM | seekingalpha.com

China's Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion

October 21 at 12:43 AM | wsj.com

China's Innovent signs $11.4 billion cancer therapy deal with Japan's Takeda

October 21 at 8:39 PM | reuters.com

Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market

October 21 at 8:25 PM | prnewswire.com

Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors

October 21 at 8:25 PM | businesswire.com

13 Best Growth Stocks Under $25 to Buy Right Now

October 21 at 8:32 AM | insidermonkey.com

Legacy Wealth Asset Management LLC Has $2.55 Million Stock Position in Takeda Pharmaceutical Co. $TAK

October 21 at 7:13 AM | marketbeat.com

Does Takeda Offer Value After Latest FDA Approval and Share Price Dip in 2025?

October 19, 2025 | finance.yahoo.com

Mantle Cell Lymphoma Pipeline 2025: Innovative Clinical Developments by 20+ Global Leaders – DelveInsight | Featuring AbbVie, Takeda, PharmaEngine, InnoCare Pharma, Guangzhou ...

October 17, 2025 | theglobeandmail.com

Sequoia Financial Advisors LLC Buys 33,451 Shares of Takeda Pharmaceutical Co. $TAK

October 17, 2025 | marketbeat.com

BioCryst inks $700M Astria buyout to challenge Takeda for rare disease market

October 16, 2025 | fiercebiotech.comF

Vanguard Personalized Indexing Management LLC Purchases 45,959 Shares of Takeda Pharmaceutical Co. $TAK

October 16, 2025 | marketbeat.com

Weiss Ratings Reiterates "Hold (C+)" Rating for Takeda Pharmaceutical (NYSE:TAK)

October 16, 2025 | americanbankingnews.com

Naviter Wealth LLC Has $723,000 Position in Takeda Pharmaceutical Co. $TAK

October 15, 2025 | marketbeat.com

Takeda Pharmaceutical's (TAK) "Hold (C+)" Rating Reaffirmed at Weiss Ratings

October 14, 2025 | marketbeat.com

US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership

October 14, 2025 | reuters.com

Nabla Bio Signs Second Takeda Collaboration to Advance AI-Driven Design of Protein Therapeutics

October 14, 2025 | businesswire.com

Callan Family Office LLC Acquires New Shares in Takeda Pharmaceutical Co. $TAK

October 14, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ROIV, TAK, INSM, and ONC Company Descriptions

Insmed NASDAQ:INSM

$158.29 -2.11 (-1.32%)

As of 11:42 AM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

BeOne Medicines NASDAQ:ONC

$310.98 -2.56 (-0.82%)

As of 11:17 AM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Roivant Sciences NASDAQ:ROIV

$17.98 +0.02 (+0.08%)

As of 11:41 AM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Takeda Pharmaceutical NYSE:TAK

$14.05 -0.09 (-0.63%)

As of 11:42 AM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ROIV, TAK, INSM, and ONC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ROIV, TAK, INSM, and ONC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ROIV, TAK, INSM, and ONC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ROIV, TAK, INSM, and ONC Company Descriptions

Insmed NASDAQ:INSM

BeOne Medicines NASDAQ:ONC

Roivant Sciences NASDAQ:ROIV

Takeda Pharmaceutical NYSE:TAK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ROIV, TAK, INSM, and ONC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ROIV, TAK, INSM, and ONC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ROIV, TAK, INSM, and ONC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ROIV, TAK, INSM, and ONC Company Descriptions

Insmed NASDAQ:INSM

BeOne Medicines NASDAQ:ONC

Roivant Sciences NASDAQ:ROIV

Takeda Pharmaceutical NYSE:TAK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools